ConvaTec Regulatory News (CTEC)

Board changes

READING, UNITED KINGDOM (29 May 2020) - Dr Ros Rivaz has advised the Board of ConvaTec Group Plc ("ConvaTec" or "the Company") that she wishes to resign as a Non-Executive Director of the Company with effect from 31 August 2020 whereupon she shall take up the role of Chair of the Nuclear Decommissioning Agency.

Dr John McAdam, Chairman, said "On behalf of the Board I would like to thank Ros for her significant contribution to ConvaTec since she became a Director in 2017, and for serving as Chair of the Remuneration Committee since March 2019. We wish her well with her new role as Chair of the Nuclear Decommissioning Agency."

This announcement is made in accordance with Listing Rule 9.6.11R(1).

Enquiries

Analysts and Investors

Mark Reynolds, Director Investor Relations, ConvaTec +44 (0)7551 036 625

ir@convatec.com

Media

Buchanan: Charles Ryland / Chris Lane / Vicky Hayns +44 (0)207 466 5000

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and has established market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. Further information can be found at www.convatecgroup.com.